Compare Equinix Inc (EQIX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Viatris Inc — how do they compare? Equinix Inc trades at $1,010.51 (market cap $100.85B), while Viatris Inc trades at $17.3 (market cap $19.44B). The key difference: Equinix Inc is far larger — about 5.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| EQIX | VTRS | |
|---|---|---|
Market Cap | $100.85B | $19.44B |
Sector | Real Estate | Health |
52-Week High | $1.12K | $17.39 |
52-Week Low | $726.09 | $8.74 |
Enterprise Value | $121.14B | $31.65B |
Dividend Yield | 1.93% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,016.33, down 0.7% on the day, with a bearish technical signal despite strong analyst support. The company reported 2025 revenue of $9.22B and net income of $1.35B, with profitability improving but recent quarterly EPS misses. Cash flow trends show aggressive capital expenditure with negative net cash flow in 2025. The stock benefits from AI infrastructure partnerships and a 74.5% analyst buy rating.
Outlook remains positive due to AI-driven demand and global data center expansion, but high valuation multiples and rising debt levels pose risks. The consensus price target of $1,110 suggests upside potential, though technical indicators signal near-term caution. Key catalysts include Q2 2026 earnings and execution on growth investments.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
